Byetta® is an injectible drug used to treat type 2 diabetes. It was approved for use in April 2005 and launched for use in June 2005. It is manufactured by Amylin Pharmaceuticals and Eli Lilly and has been used by more than 700,000 people.
During the four years the drug has been on the market, Byetta® has been known to damage the pancreas and has received two public health advisories issued by the FDA. However, the manufacturers have only put information concerning these problems in the precaution section of the label (page 11 of the label); they did not put this information in the warnings section or add a black box to the label.
The Byetta® Litigation Group educates members on the issues associated with the use of Byetta® and shares information regarding the litigation through the Group’s Document Library, list server, and scheduled education programs.
The Byetta® Litigation Group was formed in July 2009.
Girardi & Keese
1126 Wilshire Blvd.
Los Angeles, CA 90017